Melanotan I vs Palmitoyl Tripeptide-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | Palmitoyl Tripeptide-1 |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 500 mcg–2 mg |
| Frequency | 1x daily | 2x daily |
| Cycle Length | 1–4 weeks | 4–12 weeks |
| Route | subcutaneous | topical |
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | Very well-tolerated. Suitable for most skin types including sensitive skin. |
| Best For |
What They Have in Common
Melanotan I, Palmitoyl Tripeptide-1 are both commonly used for:
Key Differences
Unique to Palmitoyl Tripeptide-1:
Which Has Stronger Evidence?
| Goal | Melanotan I | Palmitoyl Tripeptide-1 |
|---|---|---|
| Skin Health & Aesthetics | high | high |
Key Studies
Melanotan I
- Use of melanotan I and II in the general population.
BMJ (Clinical research ed.), 2009
- Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.
Pharmaceutical research, 2000
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
Pharmaceutical biotechnology, 1998
Ready to Learn More?
Looking for trusted sources?